2. Search Result
Search Result
Pathways Recommended: PI3K/Akt/mTOR
Results for "

H /K ATPase inhibitor

" in MedChemExpress (MCE) Product Catalog:

100

Inhibitors & Agonists

1

Peptides

5

Natural
Products

22

Isotope-Labeled Compounds

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-100414
    Soraprazan
    2 Publications Verification

    BYK61359

    		 Proton Pump Metabolic Disease
    Soraprazan (BYK61359) is a selective, reversible K-competitive inhibitor of the H,K-ATPase (Ki=6.4 nM), with an IC50 of 0.19 μM in gastric glands. Soraprazan binds to the H,K-ATPase with a Kd of 28.27 nM. Soraprazan shows immediate inhibition of acid secretion and is more than 2000-fold selective for H,K-ATPase over Na,K- and Ca-ATPases .
    Soraprazan
  • HY-W008614
    Lansoprazole sulfone
    1 Publications Verification

    AG-1813

    		 Drug Metabolite Proton Pump Metabolic Disease
    Lansoprazole sulfone (AG-1813) is an orally active and selective inhibitor of H +, K +-ATPase. Lansoprazole sulfone can significantly stimulates gastric acid secretion by inhibiting H +, K +-ATPase. Lansoprazole sulfone has potential applications in duodenal ulcer, gastric ulcer, gastroesophageal reflux disease and Zolinger Ellison disease .
    Lansoprazole sulfone
  • HY-U00222
    S3337

    		Proton Pump Inflammation/Immunology
    S3337 is an H +, K +-ATPase inhibitor.
    S3337
  • HY-P3711
    SPAI-1

    		Na+/K+ ATPase Others
    SPAI-1 is a specific inhibitor for monovalent cation transporting ATPases. SPAI-1 is a peptide isolated from porcine duodenum, inhibits Na +, K +-ATPase and H +, K +-ATPase in vitro, stimulates Mg 2+-ATPase .
    SPAI-1
  • HY-U00042
    SKF96067

    		Proton Pump Inflammation/Immunology
    SKF96067 is a reversible inhibitor of the gastric H +/K +-ATPase.
    SKF96067
  • HY-119991
    AHR-9294

    		Proton Pump Bacterial Metabolic Disease
    AHR-9294 is an inhibitor of the H + pump enzyme and H, K-ATPase. AHR-9294 inhibits acid secretion in vivo .
    AHR-9294
  • HY-115312
    Ro 18-5364

    		Na+/K+ ATPase Others
    Ro 18-5364 is an inhibitor of gastric H+/K+ ATPase, which has the effect of inhibiting the activity of the enzyme. Ro 18-5364 has a very strong inhibitory effect on gastric mucosal H+/K+ ATPase, and the inhibitory effect is more significant at low pH. At the same time, there is no selectivity difference between the two enantiomers of H+/K+ ATPase, and its inhibitory effect can be studied and verified by a variety of experimental methods, including inhibition of enzyme activity, proton transport, and studies on its binding.
    Ro 18-5364
  • HY-15384
    Picoprazole

    		Proton Pump Metabolic Disease
    Picoprazole is a specific inhibitor of H +/K +-ATPase with IC50 of 3.1±0.4 μM.
    Picoprazole
  • HY-N10239
    Aquastatin A

    		Others Metabolic Disease
    Aquastatin A is an inhibitor of mammalian adenosine triphosphatases. Aquastatin A is isolated from a fungus identified as Fusarium aquaeductuum. Aquastatin A inhibits Na+/K(+)-ATPase with an IC50 value of 7.1 μM, and H+/K(+)-ATPase with an apparent IC50 value of 6.2 μM .
    Aquastatin A
  • HY-117225
    Pantoprazole sulfone

    		Proton Pump Inflammation/Immunology
    Pantoprazole sulfone is a metabolite of the gastric H+/K+ ATPase pump inhibitor Pantoprazole (HY-17507) .
    Pantoprazole sulfone
  • HY-17623C
    (R)-Tegoprazan

    (R)-CJ-12420; (R)-RQ-00000004

    		 Proton Pump Metabolic Disease
    (R)-Tegoprazan ((R)-CJ-12420; example 3), a benzimidazole derivative, is a potent kidney H +/K +-ATPase inhibitor with an IC50 of 98 nM of canine kidney Na +/K +-ATPase. (R)-Tegoprazan has the potential for gastrointestinal diseases research .
    (R)-Tegoprazan
  • HY-17421A
    Tenatoprazole sodium

    TU-199 sodium

    		 Proton Pump Cardiovascular Disease
    Tenatoprazole sodium (TU-199 sodium) is a proton pump inhibitor; inhibits hog gastric H +/K +-ATPase with an IC50 of 6.2 μM.
    Tenatoprazole sodium
  • HY-174258
    ATPase-IN-6

    		Proton Pump HIV SARS-CoV Infection
    ATPase-IN-6 is a H +/K +- ATPase inhibitor and a prazole derivative. ATPase-IN-6 has significant antiviral activity against multiple viruses, such as HIV-1 and SARS-COV2. ATPase-IN-6 can be used for antiviral infections research .
    ATPase-IN-6
  • HY-N2033
    Chebulinic acid
    3 Publications Verification

    		 DNA/RNA Synthesis TGF-beta/Smad Proton Pump Infection
    Chebulinic acid is a potent natural inhibitor of M. tuberculosis DNA gyrase, also can inhibit SMAD-3 phosphorylation, inhibit H+ K+-ATPase activity.
    Chebulinic acid
  • HY-103261
    SCH28080

    		Proton Pump Endocrinology
    SCH28080 is a reversible, K +-competitive inhibitor of the gastric H,K-ATPase, with a Ki of 0.12 μM. SCH28080 is an effective inhibitor of acid secretion in vivo and with anti-gastric ulcer activity .
    SCH28080
  • HY-17623D
    Tegoprazan Benzoate

    CJ-12420 Benzoate; RQ-00000004 Benzoate

    		 Proton Pump Metabolic Disease
    Tegoprazan Benzoate is the benzoate form of Tegoprazan (HY-17623). Tegoprazan (CJ-12420), a potassium-competitive acid blocker, is a potent, oral active and highly selective inhibitor of gastric H +/K +-ATPase that could control gastric acid secretion and motility, with IC50 values ranging from 0.29-0.52 μM for porcine, canine, and human H +/K +-ATPases in vitro .
    Tegoprazan Benzoate
  • HY-124158
    KR-60436

    		Proton Pump Metabolic Disease
    KR-60436 is a reversible H +/K +-ATPase inhibitor. KR-60436 can potently inhibit the metabolism of CYP1A2 substrates .
    KR-60436
  • HY-B1446
    Esomeprazole magnesium
    1 Publications Verification

    (S)-Omeprazole magnesium; (-)-Omeprazole magnesium

    		 Proton Pump Endocrinology Cancer
    Esomeprazole magnesium ((S)-Omeprazole magnesium) is a potent and orally active H +, K +-ATPase inhibitor. Esomeprazole magnesium has the potential for upper intestinal disorders and gastroesophageal reflux disease research . Esomeprazole magnesium acts as an exosome inhibitor by blocking the exosome release via the inhibition of V-H +-ATPases .
    Esomeprazole magnesium
  • HY-165569
    AU-1421

    		Potassium Channel Neurological Disease
    AU-1421 is a potassium ion (K⁺) site-directed regulator that specifically acts on various cation transport ATPases. AU-1421 can distinguish between two different K⁺-sensitive phosphorylation intermediate (E2P) states: for non-K⁺ transport type ATPases (such as the sarcoplasmic reticulum Ca²⁺-ATPase), after binding to AU-1421, it mimics the agonistic effect of K⁺, significantly accelerating the hydrolysis (dephosphorylation) of E2P. For K⁺ transport type ATPases (such as the gastric mucosa H⁺/K⁺-ATPase and the renal Na⁺/K⁺-ATPase), after binding to AU-1421, it inhibits the hydrolysis of E2P, stabilizing the phosphorylated intermediate, thereby blocking the ion transport cycle. AU-1421 can be used to study the mechanism of the potassium ion pump .
    AU-1421
  • HY-17623R
    Tegoprazan (Standard)

    CJ-12420 (Standard); RQ-00000004 (Standard)

    		 Reference Standards Proton Pump Metabolic Disease
    Tegoprazan (Standard) is the analytical standard of Tegoprazan. This product is intended for research and analytical applications. Tegoprazan (CJ-12420), a potassium-competitive acid blocker, is a potent, oral active and highly selective inhibitor of gastric H +/K +-ATPase that could control gastric acid secretion and motility, with IC50 values ranging from 0.29-0.52 μM for porcine, canine, and human H +/K +-ATPases in vitro .
    Tegoprazan (Standard)
  • HY-124235
    SK&F 97574 hydrochloride

    		Na+/K+ ATPase Others
    SK&F 97574 hydrochloride is a reversible inhibitor for H+/K+ ATPase, that reduces gastric acid secretion and promotes the healing of acid-related upper gastrointestinal ulcers .
    SK&F 97574 hydrochloride
  • HY-W008614R
    Lansoprazole sulfone (Standard)

    AG-1813 (Standard)

    		 Drug Metabolite Reference Standards Proton Pump Metabolic Disease
    Lansoprazole sulfone (Standard) is the analytical standard of Lansoprazole sulfone. This product is intended for research and analytical applications. Lansoprazole sulfone (AG-1813) is an orally active and selective inhibitor of H+, K+-ATPase. Lansoprazole sulfone can significantly stimulates gastric acid secretion by inhibiting H+, K+-ATPase. Lansoprazole sulfone has potential applications in duodenal ulcer, gastric ulcer, gastroesophageal reflux disease and Zolinger Ellison disease .
    Lansoprazole sulfone (Standard)
  • HY-17022
    Esomeprazole magnesium trihydrate
    1 Publications Verification

    (S)-Omeprazole magnesium trihydrate; (-)-Omeprazole magnesium trihydrate

    		 Proton Pump Endocrinology Cancer
    Esomeprazole magnesium trihydrate ((S)-Omeprazole magnesium trihydrate) is a potent and orally active H +, K +-ATPase inhibitor. Esomeprazole magnesium trihydrate has the potential for upper intestinal disorders and gastroesophageal reflux disease research . Esomeprazole magnesium trihydrate acts as an exosome inhibitor by blocking the exosome release via the inhibition of V-H +-ATPases .
    Esomeprazole magnesium trihydrate
  • HY-W008614S1
    Lansoprazole sulfone-13C6

    AG-1813-13C6

    		 Isotope-Labeled Compounds Proton Pump Drug Metabolite Metabolic Disease
    Lansoprazole sulfone- 13C6 (AG-1813- 13C6) is 13C labeled Lansoprazole sulfone. Lansoprazole sulfone (AG-1813) is an orally active and selective inhibitor of H +, K +-ATPase. Lansoprazole sulfone can significantly stimulates gastric acid secretion by inhibiting H +, K +-ATPase. Lansoprazole sulfone has potential applications in duodenal ulcer, gastric ulcer, gastroesophageal reflux disease and Zolinger Ellison disease .
    Lansoprazole sulfone-13C6
  • HY-17023
    Esomeprazole sodium
    2 Publications Verification

    (S)-Omeprazole sodium; (-)-Omeprazole sodium

    		 Proton Pump Bacterial Endocrinology Cancer
    Esomeprazole sodium ((S)-Omeprazole sodium) is a potent and orally active proton pump inhibitor. Esomeprazole reduces acid secretion through inhibition of the H +, K +-ATPase in gastric parietal cells. Esomeprazole acts as an exosome inhibitor by blocking the exosome release via the inhibition of V-H +-ATPases . Esomeprazole has the potential for symptomatic gastroesophageal reflux disease research .
    Esomeprazole sodium
  • HY-123184
    S 1924

    		Proton Pump Neurological Disease Metabolic Disease
    S 1924 is a potent H+, K+-ATPase inhibitor, with IC50 values of 10.3 and 1.6 μM at pH 7.4 and pH 6.0, respectively .
    S 1924
  • HY-17623
    Tegoprazan
    2 Publications Verification

    CJ-12420; RQ-00000004

    		 Proton Pump Potassium Channel Na+/K+ ATPase Inflammation/Immunology
    Tegoprazan (CJ-12420), a potassium-competitive acid blocker, is a reversible, orally active and highly selective inhibitor of gastric H +/K +-ATPase. Tegoprazan inhibits gastric acid secretion and motility against porcine, canine and human H +/K +-ATPase with IC50 values ranging from 0.29-0.52 μM in vitro. Tegoprazan significantly improves colitis and enhances the intestinal epithelial barrier function in mice. Tegoprazan is promising for research of Inflammatory bowel, gastric acid-related, motilityimpaired diseases .
    Tegoprazan
  • HY-W008614S
    Lansoprazole sulfone-d4

    AG-1813-d4

    		 Isotope-Labeled Compounds Proton Pump Others
    Lansoprazole sulfone-d4 (AG-1813-d4) is the deuterium labeled Lansoprazole sulfone. Lansoprazole sulfone-d4 is an orally active and selective inhibitor of H +, K +-ATPase. Lansoprazole sulfone-d4 can significantly stimulates gastric acid secretion by inhibiting H +, K +-ATPase. Lansoprazole sulfone-d4 has potential applications in duodenal ulcer, gastric ulcer, gastroesophageal reflux disease and Zolinger Ellison disease .
    Lansoprazole sulfone-d4
  • HY-105094
    Leminoprazole

    NC 1300O3

    		 Na+/K+ ATPase Inflammation/Immunology
    Leminoprazole (NC 1300O3) is an inhibitor for acid pump, H + K +-ATPase,. Leminoprazole stimulates the secretion and synthesis of gastric mucus, attenuates gastric ulcers. Leminoprazole is orally active .
    Leminoprazole
  • HY-W003467
    Rabeprazole Sulfide

    		Proton Pump Bacterial Infection Inflammation/Immunology
    Rabeprazole Sulfide is an active metabolite of Rabeprazole. Rabeprazole is a proton pump inhibitor that suppresses gastric acid secretion through an interaction with (H +/K +)-ATPase in gastric parietal cells. Rabeprazole markedly inhibits the motility of H. pylori. Rabeprazole has the potential for various peptic diseases treatment .
    Rabeprazole Sulfide
  • HY-100412A
    Linaprazan mesylate

    AZD-0865 mesylate

    		 Proton Pump Cancer
    Linaprazan mesylate can inhibit H+,K+ -ATPase in the stomach through K+ competitive binding. (IC 50: 1.0 ± 0.2 μM), it has a strong inhibitory effect on acid. Linaprazan (AZD0865) mesylate can be used for research on reflux esophagitis with oral activity .
    Linaprazan mesylate
  • HY-N2033R
    Chebulinic acid (Standard)

    		Reference Standards DNA/RNA Synthesis TGF-beta/Smad Proton Pump Infection
    Chebulinic acid (Standard) is the analytical standard of Chebulinic acid. This product is intended for research and analytical applications. Chebulinic acid is a potent natural inhibitor of M. tuberculosis DNA gyrase, also can inhibit SMAD-3 phosphorylation, inhibit H+ K+-ATPase activity.
    Chebulinic acid (Standard)
  • HY-109023
    Azeloprazole

    		Others Others
    Azeloprazole is a compound used to inhibit acid-related diseases. It is a proton pump inhibitor that inhibits H +,K --ATPase in pig gastric vesicles. It can effectively inhibit gastric acid secretion in the dog's gastric fistula model. The effect is long-lasting and superior to esomeprazole.
    Azeloprazole
  • HY-103261R
    SCH28080 (Standard)

    		Reference Standards Proton Pump Endocrinology
    SCH28080 (Standard) is the analytical standard of SCH28080. This product is intended for research and analytical applications. SCH28080 is a reversible, K+-competitive inhibitor of the gastric H,K-ATPase, with a Ki of 0.12 μM. SCH28080 is an effective inhibitor of acid secretion in vivo and with anti-gastric ulcer activity .
    SCH28080 (Standard)
  • HY-N7031
    (±)​-​Vasicine

    (±)​-Peganine

    		 Proton Pump Inflammation/Immunology
    (±)-Vasicine is the racemate of Vasicine. Vasicine (Peganine) significantly inhibits H +-K +-ATPase activity in vitro with an IC50 of 73.47 μg/mL. Anti-ulcer activity. Vasicine shows significant anti-secretory, antioxidant and cytoprotective effect .
    (±)​-​Vasicine
  • HY-W709055
    Pantoprazole sulfone-d6 (major)

    		Isotope-Labeled Compounds Proton Pump Inflammation/Immunology
    Pantoprazole sulfone-d6 (major) is the deuterium labeled Pantoprazole sulfone (HY-117225). Pantoprazole sulfone is a metabolite of the gastric H+/K+ ATPase pump inhibitor Pantoprazole (HY-17507) .
    Pantoprazole sulfone-d6 (major)
  • HY-17023R
    Esomeprazole sodium (Standard)

    (S)-Omeprazole sodium (Standard); (-)-Omeprazole sodium (Standard)

    		 Reference Standards Proton Pump Bacterial Endocrinology Cancer
    Esomeprazole (sodium) (Standard) is the analytical standard of Esomeprazole (sodium). This product is intended for research and analytical applications. Esomeprazole sodium ((S)-Omeprazole sodium) is a potent and orally active proton pump inhibitor. Esomeprazole reduces acid secretion through inhibition of the H +, K +-ATPase in gastric parietal cells. Esomeprazole acts as an exosome inhibitor by blocking the exosome release via the inhibition of V-H +-ATPases . Esomeprazole has the potential for symptomatic gastroesophageal reflux disease research .
    Esomeprazole sodium (Standard)
  • HY-17623S
    Tegoprazan-d6

    CJ-12420-d6; RQ-00000004-d6

    		 Proton Pump Na+/K+ ATPase Metabolic Disease
    Tegoprazan (CJ-12420; RQ-00000004), a potassium-competitive acid blocker, is a reversible, oral active and highly selective inhibitor of gastric H+/K+-ATPase that could control gastric acid secretion and motility, with IC50 values ranging from 0.29-0.52 μM for porcine, canine, and human H +/K +-ATPases in vitro. Tegoprazan significantly improves colitis in mice and enhances the intestinal epithelial barrier function. Tegoprazan is promising for research of Inflammatory bowel, gastric acid-related, motilityimpaired diseases .
    Tegoprazan-d6
  • HY-100412
    Linaprazan

    AZD0865

    		 Proton Pump Cancer
    Linaprazan (AZD0865) can inhibit H+,K+ -ATPase in the stomach through K+ competitive binding, (IC50: 1.0 ± 0.2 μM), it has a strong inhibitory effect on acid. Linaprazan (AZD0865) can be used for research on reflux esophagitis with oral activity .
    Linaprazan
  • HY-109079A
    Abeprazan hydrochloride

    DWP14012 hydrochloride; Fexuprazan hydrochloride

    		 Proton Pump Metabolic Disease
    Abeprazan hydrochloride (DWP14012 hydrochloride) is a potassium-competitive acid blocker. Abeprazan hydrochloride inhibits H +, K +- ATPase by reversible potassium-competitive ionic binding with no acid activation required. Abeprazan hydrochloride is developed as a potential alternative to proton pump inhibitor for the treatment of acid-related diseases .
    Abeprazan hydrochloride
  • HY-109079
    Abeprazan

    DWP14012; Fexuprazan

    		 Proton Pump Metabolic Disease
    Abeprazan (DWP14012) is a potassium-competitive acid blocker. Abeprazan inhibits H +, K +- ATPase by reversible potassium-competitive ionic binding with no acid activation required. Abeprazan is developed as a potential alternative to proton pump inhibitor for the treatment of acid-related diseases .
    Abeprazan
  • HY-126751
    DBM-819

    		Na+/K+ ATPase Metabolic Disease
    DBM-819 is a reversible inhibitor of H⁺/K⁺-ATPase (H +/K +-ATPase), with an IC50 value of 5 μM. DBM-819 can reversibly block gastric acid secretion by inhibiting the proton pump in the gastric mucosa. It shows significant protective effects against duodenal ulcers induced by Cysteamine (HY-77591), gastric ulcers induced by Indomethacin (HY-14397), and gastric ulcers induced by Aspirin (HY-14654), with EC50 values of 6, 3.1, and 4 mg/kg respectively. DBM-819 can be used in ulcer prevention research .
    DBM-819
  • HY-17021B
    Esomeprazole potassium salt
    2 Publications Verification

    (S)-Omeprazole potassium salt; (-)-Omeprazole potassium salt

    		 Proton Pump Bacterial Inflammation/Immunology Endocrinology Cancer
    Esomeprazole potassium salt ((S)-Omeprazole potassium salt) is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H +, K +-ATPase in gastric parietal cells. Esomeprazole potassium salt has the potential for symptomatic gastroesophageal reflux disease research .
    Esomeprazole potassium salt
  • HY-17021
    Esomeprazole
    2 Publications Verification

    (S)-Omeprazole; (-)-Omeprazole

    		 Proton Pump Bacterial Inflammation/Immunology Endocrinology Cancer
    Esomeprazole ((S)-Omeprazole) is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H +, K +-ATPase in gastric parietal cells. Esomeprazole has the potential for symptomatic gastroesophageal reflux disease research .
    Esomeprazole
  • HY-17021C
    Esomeprazole hemistrontium

    (S)-Omeprazole hemistrontium; (-)-Omeprazole hemistrontium

    		 Proton Pump Bacterial Inflammation/Immunology Endocrinology Cancer
    Esomeprazole ((S)-Omeprazole) hemistrontium is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H +, K +-ATPase in gastric parietal cells. Esomeprazole hemistrontium has the potential for symptomatic gastroesophageal reflux disease research .
    Esomeprazole hemistrontium
  • HY-17021A
    Esomeprazole magnesium salt

    (S)-Omeprazole magnesium salt; (-)-Omeprazole magnesium salt

    		 Proton Pump Bacterial Inflammation/Immunology Endocrinology Cancer
    Esomeprazole magnesium salt ((S)-Omeprazole magnesium salt) is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H +, K +-ATPase in gastric parietal cells. Esomeprazole magnesium salt has the potential for symptomatic gastroesophageal reflux disease research .
    Esomeprazole magnesium salt
  • HY-W003467R
    Rabeprazole Sulfide (Standard)

    		Reference Standards Proton Pump Bacterial Infection Inflammation/Immunology
    Rabeprazole Sulfide (Standard) is the analytical standard of Rabeprazole Sulfide. This product is intended for research and analytical applications. Rabeprazole Sulfide is an active metabolite of Rabeprazole. Rabeprazole is a proton pump inhibitor that suppresses gastric acid secretion through an interaction with (H +/K +)-ATPase in gastric parietal cells. Rabeprazole markedly inhibits the motility of H. pylori. Rabeprazole has the potential for various peptic diseases treatment .
    Rabeprazole Sulfide (Standard)
  • HY-100413
    CS-526

    		Proton Pump Inflammation/Immunology
    CS-526 is a potent, selective, reversible and orally active acid pump antagonist. CS-526 inhibits H +,K +-ATPase activity. CS-526 inhibits gastric acid secretion and prevents esophageal lesions. CS-526 has the potential for the research of gastroesophageal reflux disease .
    CS-526
  • HY-75424A
    2-(Trifluoromethyl)cinnamic acid

    		Proton Pump Inflammation/Immunology
    2-(Trifluoromethyl)cinnamic acid is a cinnamic acid derivative that inhibits the proton pump (H +/K +-ATPase), thereby reducing gastric acid secretion. 2-(Trifluoromethyl)cinnamic acid also improves delayed gastric emptying and can be used in research on gastric diseases such as acute gastritis and gastric ulcers .
    2-(Trifluoromethyl)cinnamic acid
  • HY-W003467S1
    Rabeprazole sulfide-d3

    		Isotope-Labeled Compounds Proton Pump Bacterial Infection
    Rabeprazole sulfide-d3 is the deuterium labeled Rabeprazole Sulfide (HY-W003467). Rabeprazole Sulfide is an active metabolite of Rabeprazole. Rabeprazole is a proton pump inhibitor that suppresses gastric acid secretion through an interaction with (H+/K+)-ATPase in gastric parietal cells. Rabeprazole markedly inhibits the motility of H. pylori. Rabeprazole has the potential for various peptic diseases treatment .
    Rabeprazole sulfide-d3

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: